Unifab Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 09-12-2024
- Paid Up Capital ₹ 0.10 M
as on 09-12-2024
- Company Age 8 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 523.78%
(FY 2019)
- Profit 858.83%
(FY 2019)
- Ebitda 847.29%
(FY 2019)
- Net Worth 848.61%
(FY 2019)
- Total Assets 175.27%
(FY 2019)
About Unifab Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Majid Shaikh, Mohammed Shaikh, and Mohammad Gulam serve as directors at the Company.
- CIN/LLPIN
U74999MH2016PTC285270
- Company No.
285270
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Aug 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Unifab Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Majid Shaikh  | Director | 23-Jan-2021 | Current |
| Mohammed Shaikh | Whole-Time Director | 01-Mar-2022 | Current |
| Mohammad Gulam | Whole-Time Director | 01-Mar-2022 | Current |
Financial Performance of Unifab Pharmaceuticals.
Unifab Pharmaceuticals Private Limited, for the financial year ended 2019, experienced significant growth in revenue, with a 523.78% increase. The company also saw a substantial improvement in profitability, with a 858.83% increase in profit. The company's net worth Soared by an impressive increase of 848.61%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Unifab Pharmaceuticals?
In 2019, Unifab Pharmaceuticals had a promoter holding of 86.00% and a public holding of 14.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Golden Mist Pharmaceuticals Private LimitedActive 4 years 9 daysMohammed Shaikh and Mohammad Gulam are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Unifab Pharmaceuticals?
Unifab Pharmaceuticals has a workforce of 2 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Unifab Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Unifab Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
